Saturday - April 26, 2025
FRISCO, Texas / Mar 05, 2024 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman, President and Brad Bickham, President and Chief Operating Officer, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.
In connection with the virtual conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 11:20 a.m. Eastern Time / 10:20 a.m. Central Time on Tuesday, March 12, 2024. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.
About Addus HomeCare
Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to over 49,000 consumers through 217 locations across 22 states. For more information, please visit www.addus.com.
Last Trade: | US$100.58 |
Daily Change: | 2.54 2.59 |
Daily Volume: | 95,913 |
Market Cap: | US$1.820B |
November 04, 2024 August 05, 2024 June 28, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load